Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Consolidated Net Income (2019 - 2023)

Historic Consolidated Net Income for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$45.3 million.

  • ADC Therapeutics' Consolidated Net Income rose 1293.1% to -$45.3 million in Q3 2023 from the same period last year, while for Dec 2023 it was -$153.5 million, marking a year-over-year decrease of 1175.16%. This contributed to the annual value of -$153522.0 for FY2022, which is 9993.14% up from last year.
  • Latest data reveals that ADC Therapeutics reported Consolidated Net Income of -$45.3 million as of Q3 2023, which was up 1293.1% from -$48.2 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Consolidated Net Income registered a high of -$16223.0 during Q4 2022, and its lowest value of -$126.3 million during Q2 2020.
  • Over the past 5 years, ADC Therapeutics' median Consolidated Net Income value was -$45.3 million (recorded in 2023), while the average stood at -$39.8 million.
  • In the last 5 years, ADC Therapeutics' Consolidated Net Income crashed by 54544835.92% in 2020 and then soared by 9715.3% in 2022.
  • ADC Therapeutics' Consolidated Net Income (Quarter) stood at -$35055.0 in 2019, then plummeted by 57905.99% to -$20.3 million in 2020, then skyrocketed by 97.2% to -$569831.0 in 2021, then soared by 97.15% to -$16223.0 in 2022, then crashed by 279145.52% to -$45.3 million in 2023.
  • Its Consolidated Net Income stands at -$45.3 million for Q3 2023, versus -$48.2 million for Q2 2023 and -$60.0 million for Q1 2023.